Copyright
©2014 Baishideng Publishing Group Inc.
World J Diabetes. Aug 15, 2014; 5(4): 536-545
Published online Aug 15, 2014. doi: 10.4239/wjd.v5.i4.536
Published online Aug 15, 2014. doi: 10.4239/wjd.v5.i4.536
Table 3 Comparison between carvedilol and renal denervation as therapeutic choices to reduce blood pressure and glucose levels in hypertensive type 2 diabetes mellitus patients
Therapeutic method | Mechanism of action | Medical indication | Mechanisms which explain glucose reduction | Contraindications | Side effects |
Carvedilol | α1, non-selective β-blocker, antioxidant and calcium antagonist properties[17-20] | Treatment of hypertension[21] heart failure[25] and coronary artery disease[27] | An improvement in insulin sensitivity by a reduction in sympathetic nerve activity[74,75] and free radicals[68,69] | Bronchial asthma, second-third degree atrioventricular block, sick sinus syndrome, severe bradycardia, patients with severe cardiogenic shock and heart failure who use inotropic drugs and hepatic impairement[17-20] | Frequent: edema, dizziness, bradycardia, hypotension, nausea, diarrhea and blurred vision Rare: deterioration of renal and hepatic function[17-20] |
RDN | Ablation of afferent and efferent renal nerves[51-55] | Treatment of resistant hypertension[56,57] | An improvement in insulin sensitivity by reduction in sympathetic nerve activity[56,57] | Polar or accessory arteries, renal artery stenosis, prior renal revascularization and glomerular filtration rate < 45 mL/min per 1.73 m2[56,57,62] | Renal artery dissection, postprocedural hypotension, femoral artery pseudoaneuryn, intraprocedural bradycardia[56,57] |
- Citation: Castro Torres Y, Katholi RE. Novel treatment approaches in hypertensive type 2 diabetic patients. World J Diabetes 2014; 5(4): 536-545
- URL: https://www.wjgnet.com/1948-9358/full/v5/i4/536.htm
- DOI: https://dx.doi.org/10.4239/wjd.v5.i4.536